机构：[1]Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, No. 1 Xincheng Road, Dongguan 523808, China[2]Dongguan 6th People’s Hospital, Dongguan 523008, China[3]Department of Clinical Immunology, Institute of Laboratory Medicine, Guangdong Medical College, No. 1 Xincheng Road, Dongguan 523808, China[4]Department of Clinical Laboratory, Affiliated Hospital of Guangdong Medical college, Zhanjiang 524001, China[5]Department of Laboratory Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China大德路总院检验科大德路总院检验科广东省中医院[6]Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States of America[7]Department of Microbiology and Immunology, Center for Primate Biomedical Research, University of Illinois College of Medicine, Chicago 60612, Illinois, United States of America.
Despite the recent appreciation of interleukin 35 (IL-35) function in inflammatory diseases, little is known for IL-35 response in patients with active tuberculosis (ATB). In the current study, we demonstrated that ATB patients exhibited increases in serum IL-35 and in mRNA expression of both subunits of IL-35 (p35 and EBI3) in white blood cells and peripheral blood mononuclear cells. Consistently, anti-TB drug treatment led to reduction in serum IL-35 level and p35 or EBI3 expression. TB infection was associated with expression of p35 or EBI3 protein in CD4(+) but not CD8(+) T cells. Most p35(+)CD4(+) T cells and EBI3(+)CD4(+) T cells expressed Treg-associated marker CD25. Our findings may be important in understanding immune pathogenesis of TB. IL-35 in the blood may potentially serve as a biomarker for immune status and prognosis in TB.
基金：
This work was supported by grants from
the National Natural Science Foundation of
China (81570009, 81273237, 30972779,
81101553), Natural Science Foundation of
Guangdong Province (2015A030313513),
the Key Project of Science and Technology
Innovation of Education Department of
Guangdong Province (2012KJCX0059), the
Science and Technology Project of Dongguan
(201450715200503), the Science and Technology
Project of Zhanjiang (2013C03012)
and the Science and Technology Innovation
Fund of GDMC (STIF201110, B2012078).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2015]版：
大类|3 区医学
小类|3 区医学：研究与实验3 区肿瘤学
最新[2025]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区肿瘤学
第一作者：
第一作者机构：[1]Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, No. 1 Xincheng Road, Dongguan 523808, China
共同第一作者：
通讯作者：
通讯机构：[1]Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, No. 1 Xincheng Road, Dongguan 523808, China[3]Department of Clinical Immunology, Institute of Laboratory Medicine, Guangdong Medical College, No. 1 Xincheng Road, Dongguan 523808, China[*1]Department of Clinical Immunology, Institute of Laboratory Medicine, Guangdong Medical University, No.1 Xincheng Road Songshan Lake, Dongguan 523808, P. R. China.
推荐引用方式(GB/T 7714)：
Bin Kong,Gan-Bin Liu,Jun-Ai Zhang,et al.Elevated serum IL-35 and increased expression of IL-35-p35 or -EBI3 in CD4(+)CD25(+) T cells in patients with active tuberculosis.[J].American journal of translational research.2016,8(2):623-33.
APA：
Bin Kong,Gan-Bin Liu,Jun-Ai Zhang,Xiao-Xia Fu,Wen-Yu Xiang...&Jun-Fa Xu.(2016).Elevated serum IL-35 and increased expression of IL-35-p35 or -EBI3 in CD4(+)CD25(+) T cells in patients with active tuberculosis..American journal of translational research,8,(2)
MLA：
Bin Kong,et al."Elevated serum IL-35 and increased expression of IL-35-p35 or -EBI3 in CD4(+)CD25(+) T cells in patients with active tuberculosis.".American journal of translational research 8..2(2016):623-33
